5-fluorouracil + carboplatin + interferon beta + interferon gamma + mitomycin C

This is an investigational multi-agent combination regimen consisting of five drugs with distinct mechanisms of action, used in experimental immunochemotherapy protocols for cancer. The regimen includes: - **5-fluorouracil (5-FU):** A pyrimidine antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cytotoxicity in rapidly dividing cells[3][4]. - **Carboplatin:** An organoplatinum alkylating agent that forms DNA crosslinks, inhibiting DNA replication and transcription[7]. - **Mitomycin C:** An antitumor antibiotic that acts as a bioreductive alkylating agent, causing DNA crosslinking and strand breakage. - **Interferon beta & Interferon gamma:** Recombinant cytokines with immunomodulatory effects; they enhance immune cell activity against tumor cells. This combination has been studied in phase I/II trials for metastatic colorectal cancer and other advanced malignancies. The addition of both interferons aims to boost the immune response alongside the cytotoxic effects of chemotherapy. In one study, this regimen achieved a remission rate of 47% in metastatic colorectal cancer patients with good tolerability[1]. The approach leverages both direct tumor cell killing (chemotherapy) and immune system activation (interferons).

Other names

5-FU + carboplatin + IFN-beta + IFN-gamma + mitomycin C5-fluorouracil/carboplatin/interferon beta/interferon gamma/mitomycin C combination